Nature Communications
A randomised Phase IIa trial of amine oxidase copper-containing 3 (AOC3) inhibitor BI 1467335 in adults with non-alcoholic steatohepatitis
Posted on
OUr founders
ISO 9001 Certified
OUr Institutionnal Supporters
Our network
Foundation for innovation
in Cardiometabolism and Nutrition
